Tag: Sanofi

Evotec launches a new drug discovery initiative with Sanofi

drug discovery
Evotec AG announced that it has established an initiative with Sanofi through the launch of a BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.

Sanofi is running the pilot of AI solution with Researchably

AI
Researchably (USA) announces the only AI solution which uses natural language processing (NLP) to read and review these scientific articles.

Dyadic entered into research collaboration with Sanofi-Aventis Deutschland

lab-tube
Dyadic International, a global biotechnology company, announced that it has entered into a fully funded proof of concept research collaboration with Sanofi-Aventis Deutschland GmbH.

Sanofi changes the structure of two business units

sanofi
Sanofi will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets.

Sanofi agreed to pay over $25 million to resolve corruption charges

Sanofi
Securities and Exchange Commission announced that Sanofi has agreed to pay $25 million to resolve charges that its Kazakhstan and the Middle East subsidiaries made corrupt payments to win business.

Sanofi’s blood clotting disorder drug receives EU approval

sanofi
The European Commission has granted marketing authorization for Cablivi for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.

Master classes at the III All-Russia GMP conference hit the records

August 29 was the final day of the III All-Russia GMP conference with international participation Russia and the World. Management of the pharmaceutical market growth potential.

Sanofi’s pharma plant in the Pyrenees will resume some operations

Sanofi
A month after being shut down over toxic pollution, Sanofi’s drug manufacturing plant in the Pyrenees has been authorised to resume certain operations starting mid-August.

Sanofi and REVOLUTION Medicines entered an exclusive worldwide partnership

cancer-drugs
Sanofi and REVOLUTION Medicines announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2.

Sanofi suspends production at Mourenx facility due to environmental accusations

sanofi
French pharma group Sanofi announced an immediate halt in production at a chemical factory in southwest France, in the wake of media reports that toxic waste emissions exceeded the norms.

Kirov pharma cluster participants explored biotech development in France

kirov-france
The delegation of the government of the Kirov region visited the Lyonbiopôle in France, which is largest pharmaceutical cluster in the world.

Sanofi and Advent completed negotiations for the acquisition of Zentiva

zentiva
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi's European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion

Sanofi sets up its Global R&D Operations Hub in China

sanofi-china
Sanofi is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in Chengdu, Sichuan province, China.

Evotec receives €3 million payment from Sanofi

stem cells
Evotec AG announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of €3 million to Evotec.

Evotec and Sanofi join forces to fight infectious diseases

microbiology plates
Evotec signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives.

Sanofi Pasteur and Translate Bio will cooperate on mRNA vaccines

sanofi-pasteur
Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, to develop mRNA vaccines.